International: +1-347-960-6455
Essential Hypertension Therapeutics - Pipeline Analysis 2018

Essential Hypertension Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10003 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Cardiovascular
Select License Type

Essential hypertension, also known as idiopathic hypertension, is a kind of high blood pressure for which a secondary cause is not known. It is also known as primary hypertension and can eventually lead to atherosclerosis, stroke, heart attack, heart failure, eye and kidney damage. The risk factors associated with this disease are genetic factors, diet, stress, and obesity. According to the data published by the Centers for Disease Control and Prevention, about 30,221 people died in the U.S. because of essential hypertension and hypertensive renal disease, in 2014. Essential hypertension can be treated by lifestyle changes, calcium channel blockers, beta blockers, diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, and renin inhibitors. Yuhan Corporation is in the process of developing YH22162 as a fixed dose combination small molecule for the treatment of essential hypertension. Besides Daiichi Sankyo Company Ltd. is also involved in the essential hypertension pipeline.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.